BridgeMD
Atorvastatinbehandling til patienter med de Philadelphia-negative kronisk myeloproliferative neoplasier - essentiel trombocytose, polycythemia vera og præfibrotisk myelofibrose.
EU CTIS ID: 2024-518267-35-00
What this study is testing
1. In patients with MPNs undergoing Best Available Therapy (BAT), to investigate the effect of adjuvant treatment with atorvastatin assessed by inflammatory markers and cell counts.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- WHO 2016 classified ET, PV or prePMF with thrombocytosis and/or leukocytosis. 2. Age > 18 years. 3. Expected survival > 3 years. 4. If ongoing cytoreductive treatment, this must have started > 3 months ago, and there must not be an expected change of dose or treatment type in the coming year. 5. Not taking statin beforehand
You likely can't join if
- Uncontrolled autoimmune or chronic inflammatory disorder (covers unexplained inflammatory condition, inadequately treated inflammatory condition, and treatment with strong immunosuppressive medications). 2. Other active cancer (excluding squamous cell carcinoma or basal cell carcinoma in the skin and prostate cancer treated with "watchful waiting"). 3. Pregnancy 4. Contraindications against starting atorvastatin: a. Active liver disease or persistent transaminase elevation of unknown cause. b. Concomitant use of potent CYP3A4 inhibitors c. Combination with gemfibrozil or ciclosporin d. Allergy to statins
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.